T

wo drug makers — Aimmune Therapeutics (AIMT) and AnaptysBio (ANAB) — are developing different methods to protect people against severe peanut allergy and will disclose important clinical trial results within the next two months.

Anyone with school-age children knows peanut allergy is a serious and prevalent health problem. It’s estimated that between 1.5 million to 2 million people under 18 in the U.S. have peanut allergy. Apart from scrupulous peanut avoidance, there are no approved treatments for people at risk for severe allergic reaction if exposed to even trace amounts of peanut protein.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • You wrote that in the “Phase 2 study conducted by Aimmune, 62 percent of people dosed with AR101 were able to tolerate a 600 mg peanut protein food challenge after six months compared to zero patients in a placebo arm. The biostatistical separation between the two arms of the Phase 2 study favored AR101 by 37 percent”

    I’m confused how 62% became 37%. Did they explain the math?

  • You referenced parents with school-aged children…
    Both companies are attempting to treat peanut allergies by different approaches, for different patient populations. AIMT is target 4-17 year-olds with AR-101 desensitization. Immunomodualting drugs such as ANAB’s ANB020 are for adults only.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.